Search Results

Baxter Receives CE Marking and Australian Regulatory Approval for Evo IQ Syringe Infusion System, Building on Smart Pump Platform

Baxter International Inc. (NYSE:BAX), a leader in innovative technology for medication delivery, today announced CE marking and regulatory approval from Australia’s Therapeutic Goods Administration (TGA) for the Evo IQ Syringe Infusion System. The company expects hospitals in the United Kingdom, Ireland, Greece, Australia and New Zealand to be among the first to receive the new system, with additional countries to follow in a series of planned regulatory submissions.

Understanding Continuous Renal Replacement Therapy (CRRT) in COVID-19 Management

COVID-19 is affecting patients in many yet-to-be-understood ways. One of its unexpected impacts? Acute kidney injury (AKI), which is sudden kidney failure usually due to infection or trauma. During AKI, the kidneys stop working and fluid and uremic toxins build up in the body.

Supporting Nurses on the Front Lines

During COVID-19, our clinical educators continue to educate front-line nurses through virtual training sessions. 

Celebrating a Successful Career in Healthcare

Senior leader reflects on importance of mentorship after receiving prestigious industry award

Baxter Announces Results of Clinical Trial on Benefits of Dynamic Fluid Management in Septic Shock Patients

Baxter International Inc. (NYSE:BAX), a leader in innovative technology for medication delivery, today announced results of the Fluid Response Evaluation in Sepsis Hypotension and Shock (FRESH) study using the Starling Fluid Management Monitoring System, recently published in CHEST.

Caring for Our Patients Goes Above and Beyond

Our employees keep patients' health and safety front and center

Save the Children: A Special Effort During COVID-19

A $1 million grant from the Baxter International Foundation is helping further Save the Children’s global, dynamic initiatives to provide emergency relief for children and families during COVID-19.   

Baxter Increases Dividend and Declares Quarterly Dividend

Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced an increase in the company’s quarterly cash dividend to a rate of $0.245 per share of common stock. This represents an approximately 11% increase over the previous quarterly dividend rate of $0.22 per share. Baxter’s Board of Directors declared the dividend payable on July 1, 2020, to stockholders of record as of June 5, 2020.

Baxter Reports First-Quarter 2020 Results

Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported results for the first quarter of 2020. 

Lending Resources to Expand Our Impact

Our employees are doing whatever it takes to help in this time of crisis